Download PDF
Neurochirurgie Scan 2014; 02(04): 301-315
DOI: 10.1055/s-0034-1390748
Fortbildung
Neuroonkologie
© Georg Thieme Verlag KG Stuttgart · New York

Strahlennekrose im Gehirn: Bildgebungsmerkmale und Abgrenzung zum Tumorrezidiv

Dietmar Krex
,
Kay Engellandt
Further Information

Publication History

Publication Date:
22 October 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Effektivität der adjuvanten Strahlentherapie nach malignen hirneigenen Tumoren und Metastasen ist vielfach belegt. Allerdings ist diese Therapie mit dem Risiko einer Strahlennekrose assoziiert, die Monate, sogar Jahre nach der Behandlung auftreten kann.

 

  • Literatur

  • 1 Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-1588
    CrossrefGoogle Scholar
  • 2 Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
    CrossrefPubMedGoogle Scholar
  • 3 Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003
    CrossrefPubMedGoogle Scholar
  • 4 Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. a randomized controlled trial. JAMA 2006; 295: 2483-2491
    CrossrefGoogle Scholar
  • 5 Baumert BG, Rutten I, Dehing-Oberije C et al. A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys 2006; 66: 187-194
    CrossrefGoogle Scholar
  • 6 Yoo H, Kim YZ, Nam BH et al. Reduced local recurrence of a single brain metastasis through microscopic total resection. J Neurosurg 2009; 110: 730-736
    CrossrefGoogle Scholar
  • 7 Gans JH, Raper DM, Shah AH et al. The role of radiosurgery to the tumor bed after resection of brain metastases. Neurosurgery 2013; 72: 317-325
    CrossrefGoogle Scholar
  • 8 Kocher M, Wittig A, Piroth MD et al. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 2014; 190: 521-532
    CrossrefGoogle Scholar
  • 9 Fink J, Born D, Chamberlain MC. Radiation necrosis. Relevance with respect to treatment of primary and secondary brain tumors. Curr Neurol Neurosci Rep 2012; 12: 276-285
    CrossrefGoogle Scholar
  • 10 Lawrence YR, Li XA, el NI et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010; 76: 20-S27
    CrossrefGoogle Scholar
  • 11 Mayer R, Sminia P. Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 2008; 70: 1350-1360
    CrossrefGoogle Scholar
  • 12 Macdonald DR, Cascino TL, Schold Jr SC et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280
    Google Scholar
  • 13 Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas. response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-1972
    CrossrefGoogle Scholar
  • 14 Brandsma D, Stalpers L, Taal W et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9: 453-461
    CrossrefGoogle Scholar
  • 15 Brandes AA, Tosoni A, Spagnolli F et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment. Pitfalls in neurooncology. Neuro Oncol 2008; 10: 361-367
    CrossrefGoogle Scholar
  • 16 Hygino da Cruz Jr LC, Rodriguez I, Domingues RC et al. Pseudoprogression and pseudoresponse. Imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011; 32: 1978-1985
    CrossrefGoogle Scholar
  • 17 Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 2009; 27: 1275-1279
    CrossrefGoogle Scholar
  • 18 Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192-2197
    CrossrefGoogle Scholar
  • 19 Juratli TA, Engellandt K, Lautenschlaeger T et al. Is there pseudoprogression in secondary glioblastomas?. Int J Radiat Oncol Biol Phys 2013; 87: 1094-1099
    CrossrefGoogle Scholar
  • 20 Norden AD, Drappatz J, Muzikansky A et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2009; 92: 149-155
    CrossrefGoogle Scholar
  • 21 Radbruch A, Lutz K, Wiestler B et al. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol 2012; 14: 222-229
    CrossrefGoogle Scholar
  • 22 Wang LL, Leach JL, Breneman JC et al. Critical role of imaging in the neurosurgical and radiotherapeutic management of brain tumors. Radiographics 2014; 34: 702-721
    CrossrefGoogle Scholar
  • 23 Glaudemans AW, Enting RH, Heesters MA et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 2013; 40: 615-635
    CrossrefGoogle Scholar
  • 24 Kong DS, Kim ST, Kim EH et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas. the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011; 32: 382-387
    CrossrefGoogle Scholar
  • 25 Yang LJ, Zhou CF, Lin ZX. Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. Cancer Invest 2014; 32: 31-36
    CrossrefGoogle Scholar